Rtw Investments Reduces $13M in Jade Biosciences, Inc. ($JBIO)

RTW Investments has significantly trimmed its position in Jade Biosciences, Inc. (NasdaqCM: JBIO), according to its latest 13F filing with the SEC. The investment firm slashed its holdings by 876,068 shares, a 60% reduction, leaving it with 573,205 shares valued at approximately $8.79 million. This adjustment reflects the firm's holdings as of the reporting period and may not represent its current position.

What Changed in RTW Investments' Jade Biosciences Position

RTW Investments cut its stake in Jade Biosciences by 60%, selling off 876,068 shares. Before the reduction, RTW held 1,449,273 shares. Following the sale, it now holds 573,205 shares, valued at about $8.79 million. This move suggests a significant shift in the firm's investment strategy concerning Jade Biosciences.

Other Institutional Activity in Jade Biosciences

Other major funds have also been active in Jade Biosciences. FMR LLC increased its holdings by 190,935 shares, bringing its total to 7,085,423 shares worth around $99.55 million. Bellevue Group AG added 160,399 shares, ending with 3,501,502 shares valued at about $49.20 million. Meanwhile, Fairmount Funds Management LLC, RA Capital Management, L.P., and Venrock Adviser, LLC maintained their positions without any share changes.

Jade Biosciences Stock Snapshot

Shares of Jade Biosciences trade on the NasdaqCM at $15.34. The company has a market cap of approximately $933.6 million. Jade Biosciences is currently not profitable, so it doesn't have a meaningful P/E ratio. The stock's 52-week range is between $6.61 and $28.00, with a 50-day moving average of $21.20 and a 200-day moving average of $14.48. The company's current ratio stands at 14.29, indicating strong liquidity, with a quick ratio of 13.96 and a debt-to-equity ratio of 0.29.

Recent Earnings

Jade Biosciences reported an EPS of -$2.63, reflecting its unprofitability. The company's next earnings report is expected on August 13, 2026. The biotech firm focuses on developing therapies for autoimmune diseases, with several products in various stages of development.

Insider Buying and Selling at Jade Biosciences, Inc.

On June 9, 2026, several insiders, including Lavelle Erin, Klein Lawrence Otto, Fairmount Funds Management LLC, Dobmeier Eric, and Cain Christopher, each purchased 34,843 shares. Additionally, Bradford Dahms, the CFO, bought 37,813 shares on February 12, 2026. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 2, 2026, Wedbush maintained its buy rating on Jade Biosciences with a $45 price target. A day earlier, BTIG reaffirmed its buy rating, setting a high target of $74. HC Wainwright & Co. also maintained a buy rating with a $55 target. Overall, the stock has a strong buy consensus among analysts, with a mean price target of $49 based on seven opinions.

About Jade Biosciences

Jade Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapies for inflammation and immunology conditions, particularly in autoimmune diseases. The company is working on several projects, including JADE101, a monoclonal antibody currently in phase 1 clinical trials. Jade Biosciences collaborates with Paragon Therapeutics and is led by CEO Tom Frohlich.

Bottom Line

RTW Investments' decision to cut its stake in Jade Biosciences by 60% is a notable development in the biotech firm's institutional ownership landscape. Investors often track these filings to gauge fund managers' confidence in a stock's future. However, it's important to remember that 13F filings are backward-looking and may not reflect current positions.